Table of Contents
Volume 2013 (2013), Article ID 183616, 10 pages
Review Article

Prevention and Treatment of Venous Thromboembolism with New Oral Anticoagulants: A Practical Update for Clinicians

1Division of Hematology and Oncology, The Brooklyn Hospital Center, 121 Dekalb Avenue, Brooklyn, NY 11201, USA
2Section of Thrombosis and Benign Hematology, The University of Texas MD Anderson Cancer Center, Unit 1464, 1515 Holcombe Boulevard, Houston, TX 77030, USA

Received 7 September 2012; Revised 11 January 2013; Accepted 17 January 2013

Academic Editor: Juan F. Viles-Gonzalez

Copyright © 2013 Nay Min Tun and Thein Hlaing Oo. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Traditional anticoagulants, such as warfarin and enoxaparin, have several limitations, including parenteral administration, need for laboratory monitoring, and ongoing dose adjustment, which may limit optimal patient care. Newer oral anticoagulants, such as direct thrombin inhibitors (e.g., dabigatran etexilate) and direct factor Xa inhibitors (e.g., rivaroxaban, apixaban, and edoxaban), have been developed to overcome these drawbacks, and thereby improve patient care. Several of these agents have been approved for use in the prevention and treatment of venous and/or systemic thromboembolism. The objective of this paper is to provide an overview of the available clinical trial data for these new oral anticoagulants in the prevention and treatment of venous thromboembolism and a practical update for clinicians.